Pancreatic Cancer Research

ResearcherThe Wistar InstituteActive in the last 2 years

Ellen Puré

Matched on ORCID iD 0000-0003-2107-3711; OpenAlex author ID A5004098027; NIH RePORTER profile ID 1864184. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
2
Collaborators
10
Papers, trials and grants by year

2014: 1 grant · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer. Co-author DOI 10.1038/s41556-025-01697-8↗
  2. Mechanisms of PDAC subtype heterogeneity and therapy response. Co-author DOI 10.1016/j.trecan.2022.08.005↗
  3. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci.insight.92232↗

Grants 1

  1. The role of the stromal cell surface protease FAP in pancreatic cancer R21CA169741↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Espinet · 1 shared paper, 2022 · strength 0.22
  2. Shiv K. Singh · 1 shared paper, 2022 · strength 0.22
  3. Lukas Klein · 1 shared paper, 2022 · strength 0.22
  4. David Tsai Ting · 1 shared paper, 2025 · strength 0.17
  5. Taslim Ahmed Al-Hilal · 1 shared paper, 2025 · strength 0.17
  6. Matteo Ligorio · 1 shared paper, 2025 · strength 0.17
  7. David Lagares · 1 shared paper, 2025 · strength 0.17
  8. Raghu Kalluri · 1 shared paper, 2025 · strength 0.17
  9. Albert Lo · 1 shared paper, 2017 · strength 0.07
  10. Chung‐Pin Li · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.